前列腺癌的治疗(7)
12. Labrie F. Endocrine therapy for prostate cancer. Endocrin and Met Clin North Am, 1991, 20:845.
13. Tapley ME. Mutation of athe androgen-receptor gene in metastatic androgen independent prostatic cancer. N Eng J Med, 1993, 1995, 332:1393.
14. Tiley WD, Hickey TE, Bentel JM. Mutation in the androgen receptor gene are associated with progression of human prostate cancer to androgen indepedence. Clin Cancer Res, 1996, 2:227.
15. Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol, 1996, 155:209.
16. Prostate Cancer Trialist's Colloborative Group. Maximum androgen blockade in advanced prostate cancer. An overview of 22 randomized trials with 3283 death in 5710 patients. The Lancet, 1995, 346:265.
17. Kelly WK, Scher HI. Prostatic specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol, 1993, 149:607.
18. Figg WD. PSA decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med, 1995, 98:412.
19. Dupont A, Cusan L, Labrie F. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol, 1993, 150:908.
20. Kennealey GT, Barrington J , Furr A. Use of nonsteroidal anti-androgen Casodex in advanced prostate cancer. Urol Clin North Am, 1991, 18:99.
21. Goldenberg. Intermittent androgen suppression therapy for prostate cancer. Urol, 1995,45:839.
22. Chodak GW. Single agent therapy with bicalutamide: A comparison with medical and surgical castration in the treatment of advanced prostate cancer. Urol, 1995,46:849.
23. Smith PH. Hormonal manipulation of metastatic prostate cancer. Current Opinion in Urol, 1995, 5:243.
24. Harris DR, Savell J, Apoptosis and the prostate. Brit J Urol, 1995, 55:1937.
25. Steiner MS, ZHAO-Zong Zhod, Barrack ER. Expression of TGF-β1 in prostate cancer. Endocrinology, 1994, 135:2240.
26. Barnes J, Wall N, Steiner MS. Bone morphogenetic protein-6 expression in normal and malignant prostate. World J Urol, 1995, 13:337.
27. Khanna A. Bao Gui Li , Peixin Li et al: Traurforming gvowth factor-β1: Regulation with a TGF-β1 antisenre Oligomer. Kid Lnt, 1996, 19,Suppl 53 s-2.
28. Linsley P. Distinct role of CD28 and cytotoxic T lymphocyte-associated molecule-4 receptor (CTLA-4) during T cell activation. J Exp Med, 1995, 181:1896., http://www.100md.com(鲍镇美)
13. Tapley ME. Mutation of athe androgen-receptor gene in metastatic androgen independent prostatic cancer. N Eng J Med, 1993, 1995, 332:1393.
14. Tiley WD, Hickey TE, Bentel JM. Mutation in the androgen receptor gene are associated with progression of human prostate cancer to androgen indepedence. Clin Cancer Res, 1996, 2:227.
15. Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol, 1996, 155:209.
16. Prostate Cancer Trialist's Colloborative Group. Maximum androgen blockade in advanced prostate cancer. An overview of 22 randomized trials with 3283 death in 5710 patients. The Lancet, 1995, 346:265.
17. Kelly WK, Scher HI. Prostatic specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol, 1993, 149:607.
18. Figg WD. PSA decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med, 1995, 98:412.
19. Dupont A, Cusan L, Labrie F. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol, 1993, 150:908.
20. Kennealey GT, Barrington J , Furr A. Use of nonsteroidal anti-androgen Casodex in advanced prostate cancer. Urol Clin North Am, 1991, 18:99.
21. Goldenberg. Intermittent androgen suppression therapy for prostate cancer. Urol, 1995,45:839.
22. Chodak GW. Single agent therapy with bicalutamide: A comparison with medical and surgical castration in the treatment of advanced prostate cancer. Urol, 1995,46:849.
23. Smith PH. Hormonal manipulation of metastatic prostate cancer. Current Opinion in Urol, 1995, 5:243.
24. Harris DR, Savell J, Apoptosis and the prostate. Brit J Urol, 1995, 55:1937.
25. Steiner MS, ZHAO-Zong Zhod, Barrack ER. Expression of TGF-β1 in prostate cancer. Endocrinology, 1994, 135:2240.
26. Barnes J, Wall N, Steiner MS. Bone morphogenetic protein-6 expression in normal and malignant prostate. World J Urol, 1995, 13:337.
27. Khanna A. Bao Gui Li , Peixin Li et al: Traurforming gvowth factor-β1: Regulation with a TGF-β1 antisenre Oligomer. Kid Lnt, 1996, 19,Suppl 53 s-2.
28. Linsley P. Distinct role of CD28 and cytotoxic T lymphocyte-associated molecule-4 receptor (CTLA-4) during T cell activation. J Exp Med, 1995, 181:1896., http://www.100md.com(鲍镇美)